MARSEILLE, France, August 10, 2026

Innate Pharma SA announced plans to initiate the TELLOMAK-3 confirmatory Phase 3 study of lacutamab in patients with cutaneous T-cell lymphoma (CTCL), subject to the closing of its strategic partnership with Sobi. The planned Phase 3 program represents a key step toward a potential accelerated approval filing for lacutamab in Sézary syndrome (SS) based on Phase 2 TELLOMAK data. Under the proposed partnership, Innate will conduct the TELLOMAK-3 study, while financial proceeds from the transaction are intended to support the clinical program and regulatory filing. The agreement includes a $75 million upfront payment, payable upon closing, which Innate expects could extend its projected cash runway through the third quarter of 2027. Transaction closing remains subject to customary conditions, including antitrust clearance.

TELLOMAK-3 to Support Potential Accelerated Approval

The planned TELLOMAK-3 Phase 3 trial is designed as a confirmatory study in CTCL, including Sézary syndrome and mycosis fungoides, two forms of the rare blood and skin cancer. The study is expected to include patients who have failed at least one prior systemic therapy. A confirmatory cohort in Sézary syndrome is intended to support a potential accelerated approval pathway, while a registrational cohort in mycosis fungoides is intended to support a potential full approval. Progression-free survival (PFS) is planned as the primary endpoint for the mycosis fungoides cohort. The advancement of lacutamab into Phase 3 follows clinical development under the TELLOMAK program and represents a transition toward late-stage clinical and regulatory execution.

Lacutamab Targets KIR3DL2 in Rare T-Cell Lymphoma

Lacutamab is an investigational first-in-class anti-KIR3DL2 antibody being developed for CTCL. KIR3DL2 is a target expressed in Sézary syndrome and certain other CTCL populations, providing the biological rationale for lacutamab’s development. The program has received several regulatory designations, including FDA Fast Track, FDA Breakthrough Therapy, FDA and EU Orphan Drug, and EMA PRIME designations for relevant CTCL and Sézary syndrome indications. Sézary syndrome is a rare and aggressive leukemic form of CTCL, while mycosis fungoides is the most common CTCL subtype. Innate intends to use the Phase 3 program and existing clinical data to advance lacutamab toward potential regulatory approval.

Advertisement

cGxPJobs Banner

Innate Pharma Appoints Markus Jensen as Chief Medical Officer

Innate also announced the appointment of Markus Jensen as Chief Medical Officer and member of the Executive Leadership Team, effective September 1, 2026. Jensen will succeed Sonia Quaratino and is expected to lead clinical and regulatory execution as Innate advances lacutamab and prepares for upcoming development milestones for IPH4502 and monalizumab. Jensen joined Innate in 2024 as head of clinical pharmacology and has served as global clinical lead for key company programs, including IPH4502. He brings more than 25 years of experience across clinical medicine, academic research, and the pharmaceutical industry, including more than 16 years in leadership roles at Bayer focused on oncology and clinical development. Innate said the leadership transition is intended to maintain continuity as the company enters an important phase of clinical development.

Source: Innate Pharma, release